| Chemical Properties | Back Directory | [Boiling point ]
597.7±50.0 °C(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 50 mg/mL (186.42 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Cedazuridine (E7727) (Compound 7a) is an orally active cytidine deaminase (CDA) inhibitor with an IC50 value of 0.4 μM. Cedazuridine can be used for cancer research[1]. | [in vivo]
Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models[2]. | Animal Model: | Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models[2] | | Dosage: | 3 mg/kg | | Administration: | Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days | | Result: | Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model. |
| Animal Model: | NSGS male mice[2] | | Dosage: | 1, 3, 10 and 30 mg/kg | | Administration: | Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies) | | Result: | Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA. |
| [storage]
4°C, protect from light | [References]
[1] Ferraris D, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014 Mar 27; 57(6):2582-8. DOI:10.1021/jm401856k
[2] Ramsey H E, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncology, 2020, 15(2): 231-240. |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
http://m.is0513.com/ShowSupplierProductsList927327/0.htm |
|